ArticleCancer science2026
WDR12 Promotes Glucose Metabolism via PFKFB4 Upregulation in Gastric Cancer.
Article in Cancer science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Metabolic reprogramming is a hallmark of gastric cancer (GC); however, the role of transcriptional regulators in modulating glycolysis remains incompletely understood. By integrating proteomic, transcriptomic, and CRISPR-based functional screening datasets, we identified WDR12, a WD40-family protein that is upregulated in GC and associated with poor patient survival. WDR12 silencing suppressed GC cell proliferation and tumor growth in vitro and in vivo and markedly reduced glycolytic flux. Mechanistically, WDR12 interacts with TDP43 and promotes its occupancy at the PFKFB4 promoter, thereby increasing PFKFB4 transcription. Restoration of PFKFB4 expression partially rescued the metabolic and proliferative defects caused by WDR12 knockdown. Together, these findings implicate WDR12 in GC metabolic reprogramming and suggest a potential metabolic vulnerability associated with WDR12-dependent regulation of PFKFB4 through TDP43.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.